In my latest column for MPO, I discuss the risks new weight-loss drugs (GLP1s) may pose to OEMs and contract manufacturers. Heavy Harm or Slim Chance? The Impact of GLP1s on Medtech The highest existential risk is not to OEMs but to contract manufacturers specializing in the areas where GLP1s will delay surgeries. Read the column here.
AS Freeman in the news
I am honored to present The State of the Medtech Industry keynote address on October 18th at the MPO Summit in San Diego. I’ll cover the forces changing product lines and potentially introducing new competitors into the medtech supply chain.
Atalys has acquired precision moldmaker ROMOLD, Inc. of Rochester, New York. A.S. Freeman Advisors, LLC advised ROMOLD on this transaction. For more information please contact Tony Freeman. Anthony S. Freeman A.S. Freeman Advisors, LLC (917) 868-0772 tfreeman@asfreeman.com asfreeman.com
My latest piece for MPO Magazine discusses business strategies for the medical device supply chain in response to two trends: the rise of reliance on contract manufacturers vs OEMs, and supply chain consolidation.
Two strategies have emerged: the integrated contract manufacturer approach, and the specialist niche approach. I discuss the advantages and disadvantages of each, and opportunities for strategic expansion.
My latest, “Digital Devices, OEMs, and the Supply Chain: The End of the World as We Know It”, out today in MPO Magazine. Introduction: Even casual readers of OEM product websites and the device industry press are aware medical devices contain increasing amounts of digital technology. Putting numbers to the trend, recent Medtronic product announcements show 13 of 17 new products and 24 of 27 of planned products are digitally enabled. Of MPO’s Top 30 OEMs, 26 offer or plan to sell analytics or artificial intelligence products. Nine of the Top 30 offer or have announced robotic surgery devices. Another four are concentrating on digital products to enhance robotic systems. Driving these innovations are economics. Digitally capable, linked devices often produce superior outcomes to mechanical and electromechanical devices that have been the mainstays of OEM product lines for decades. Superior results often lead to lower cost per procedure, pleasing the governments and insurance companies worldwide that pay for healthcare. Read the entire article here, and please get in touch with any comments or questions.
Dear Colleague, Below please find a link to an article I wrote for the current online version of Medical Product Outsourcing magazine. The brief piece discusses the short, medium, and long-term effects of the coronavirus pandemic on medical device supply chains. https://www.mpo-mag.com/issues/2020-04-01/view_columns/covid-19s-impact-on-the-medical-device-supply-chain I look forward to your thoughts on the subject. Please contact me at tfreeman@asfreeman.com. Stay safe and well.